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Regenerative medicine provides different therapy alternatives alongside gold stan-
dard autogenous grafts for the treatment of periodontal or peri-implant os-
seous defects. Continuing progress in the field of alloplastic bone substitutes
has yielded promising solutions to the appropriate indications with the mem-
brane technique either alone or in combination with enamel matrix derivatives.
Their clinical outcomes, however, still require critical discussion.
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INTRODUCTION
For over two decades regenerative therapy has
been finding its way into the disciplines of period-
ontology and implantology. Bone graft substitutes
are used for the periodontal reconstruction of sup-
portive tissue and for implantological bone augmen-
tation and therapy of peri-implant lesions, thus pro-
viding an alternative to autologous bone grafts,
which require an intraoral or extraoral second entry,
depending on the indication and quantity needed.
The development of biological-alloplastic osteocon-
ductive bone reconstruction materials, which prima-
rily aim at bony defect regeneration not only in phys-
ical but also in biological terms, has steadily gained
importance during recent years [7, 13, 15]. Beside
these alloplastic bone substitutes, primarily used for
implant-supporting therapy, the scope of the mate-
rials used in periodontal regenerative therapy has
been broadened by membrane systems used accord-
ing to the principles of guided tissue regeneration
(GTR) and the application of enamel matrix deriva-
tives (EMD).
REGENERATIVE TREATMENT
OF PERIODONTAL DEFECTS
The objective of periodontal therapy is a signifi-
cant reduction in pocket depth and a gain of clinical
attachment, with treatment mainly including mechan-
ical debridement of root and tooth surfaces (Fig. 1).
Large defects or unfavourable pocket configurations,
where complete healing is not achieved by mechan-
ical debridement, may lend themselves to defect fill-
ing, not only in order to achieve physiological
Figure 1. A. X-ray presentation of periodontal bone defect 34
and 36 with loss of tooth 35; B. Periodontal bone defect with pe-
riodontal testing probe.
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bone morphology but also to improve the healing
prospects of the tooth root in the alveolus [11]. Be-
side the initially exclusive application of barrier mem-
branes, bone grafts or bone substitutes have been
used more often (Fig. 2).
BONE GRAFTS AND BONE SUBSTITUTES
Lost bone may be replaced by autogenous, al-
logenous or xenogenous bone grafts or, alterna-
tively, treated using alloplastic bone substitutes.
Good results in the treatment of periodontal bone
loss have been obtained using bone grafts. Both
autogenous (formed from a natural part of the
body) or allogenous (foreign to the body) grafts
are of human origin by definition. Normally the chin
area, the tuber region and the toothless jaw seg-
ments serve as donor regions. In the treatment of
periodontal osseous defects such intraoral bone
transplantation, leading to formation of new ce-
mentum, periodontal ligament and alveolar bone
is, therefore, superior to extraoral transplantation
(e.g. iliac crest) with the increased risk of ankylosis
and root resorption. However, the quantity of avail-
able bone is per se limited, which makes extraoral
bone harvesting inevitable in severe, albeit rare,
cases of bone loss. Generally, autogenous bone
grafting in intrabony alveolar defects yields a clini-
cal defect filling of 25 to 50% [3].
Allogenous bone is produced from long tubular
bones of multi-organ donors. In contrast to autoge-
nous bone grafts, the demineralised freeze-dried
bone allografts (DFDBA) are harvested without the
burden of a second surgical entry and are available
in an unlimited quantity. A disadvantage is the po-
tential danger of a virus infection, although the risk of
disease transmission is estimated at only 1:1 million to
1:8 million, depending on the tissue preparation [11].
Xenogenous bone grafts (e.g. Bio-Oss®) have long
been used in the treatment of periodontal bone de-
fects. These materials are produced from animal bone
and cannot be used until they have undergone suf-
ficient sterilisation and deproteinisation. Thermical-
ly (> 1.200 degrees) and chemically treated bovine
bone has elastic modules similar to intact bone and
is available in huge quantities. However, problems
remain regarding the immunological situation, the
residual infection risk and patient acceptance.
Many animal experiments and patient studies
show that periodontal regeneration occurs after xe-
nogenous bone grafting [2, 9]. Regenerative results
were enhanced by improved wound management
(application of collagen membranes) [8] (Fig. 3).
New-generation alloplastic bone substitutes on
the basis of anorganic bone mineral-related calci-
um phosphate ceramics (a-tricalcium phosphate,
b-tricalcium phosphate and hydroxyapatite) show
the best osteoconductive properties with respect
to the desired bone reconstructive function. They
are used for critical defect filling with increasing
clinical success.
The outcome of periodontal supportive tissue
reconstruction depends upon defect configuration
as much as upon the material applied. Narrow three-
walled pockets represent the best conditions for vi-
tal preservation and substitution with least risk of
infection [11]. a- and b-tricalcium phosphate (TCP)
are produced similarly to the synthetic hydroxyap-
atite ceramics (HA ceramics), although they display
different resorption properties. Within the body
a-TCP partially or completely hydrolyses to hy-
droxyapatite and is, therefore, hardly degradable
like the latter. The novel nanoporous hydroxyapa-
tites, however, promise a distinctly improved resorp-
tion behaviour supposed to correspond to that of
b-tricalcium phosphates (e.g. Cerasorb®, Curasan-
Pharma GmbH, Kleinostheim, Germany) which are
degraded almost completely. However, the use of
b-tricalcium phosphate in the treatment of perio-
dontal bony defects has been critically discussed in
the literature [12].
Figure 2. A. Periodontal bone loss (sketch); B. Periodontal bone
loss with application of bone substitute.
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Figure 3. A. Periodontal bone loss with pronounced bone defect;
B. Bone defect filled up with bone substitute.
BA
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Since 1989 coralline calcium carbonate (e.g. Bio-
coral®, Inoteb, B.P. Saint-Gonnery, France) as a pro-
tein-free and sterilised natural coral skeleton has been
approved for application in humans. Mainly after
implantation of this material in the mandible, the
zygomatic bone and the frontal calvarium, healing
proceeds without problems [14]. The absence of
specific proteins minimises the risk of immunologi-
cal reactions. In the treatment of periodontal bony
defects, however, the use of coralline bone substi-
tutes does not yield the desired outcome.
MEMBRANE APPLICATION
Another treatment approach for periodontal os-
seous defects utilises the self-healing effect of bone.
This method aims to restore the lost periodontal
structures by a differentiated tissue response and is
referred to as “guided tissue regeneration” (GTR)
using resorbable or non-resorbable membranes. This
principle implies the creation of a secluded hollow
space, in which bone tissue regenerates but gingival
connective tissue is prevented from growing. The
hollow space is filled with bone, bone reconstructive
material or a mixture of both. Subsequently, a slowly
resorbable membrane is inserted as a physical barri-
er. In consequence, desmodontal cells are the first
to form on the root surface of the tooth. These new
desmodontal structures then coalesce with the gin-
gival connective tissue, thus leading to elimination
of the periodontal pocket.
The use of resorbable membranes involves vari-
ous polylactides and copolymers of polylactides/
polyglycolides, while filter membranes and polytet-
rafluorethylene (Teflon) have been successfully used
as non-resorbable materials. We have to consider,
however, that a surgical re-entry is required for the
removal of non-resorbable membranes. The use of
membranes permits combination with bone grafts
or bone substitute materials.
ENAMEL MATRIX DERIVATIVES
Studies on tooth development conducted by
Hammarström in 1997 [5] showed that acellular ce-
mentum is formed as soon as dental follicle cells
come into contact with an endogenous or exoge-
nous enamel matrix. On the basis of these findings
attempts have been made to integrate enamel ma-
trix proteins into periodontal regenerative therapy
as a possible treatment alternative. The application
of EMDOGAIN® (BIORA AB, Malmö, Sweden), a hy-
drophobe mixture of enamel matrix proteins pro-
duced from the tooth germs of young pigs, to the
debrided root surface aims to mimic the cell-matrix
interaction of embryogenesis with the associated
formation of acellular cementum, which plays a key
role in the periodontal regeneration of intrabony
defects and, therefore, is supposed to improve the
latter (Fig. 4).
Numerous studies, such as that by Heijl et al. [6],
who applied EMDOGAIN® to infra-alveolar bone
pockets and subsequently observed the formation
of new cementum, periodontal ligament, and a 66%
defect filling with new bone after 36 months, ap-
pear to prove the effectiveness of this therapy con-
cept.
However, the use of EMDOGAIN®, which is com-
posed of purified amelogenins, has the disadvan-
tages that it can be used only in existing periodontal
bone defects and not in implantology and that its
effects are not fully predictable [13].
PERI-IMPLANT BONE REGENERATION
In the field of implantology a deficient bone sup-
ply in the implantation area on the one hand and
a loss of peri-implant bone as a result of peri-im-
plantitis on the other hand are often a great chal-
lenge to the dental practitioner. Numerous augmen-
tative procedures with their respective advantages
and disadvantages as mentioned above with respect
to periodontal regenerative therapy are also utilised
for peri-implant bone regeneration. Research and fur-
ther development of bioceramic bone substitute
materials on a calcium phosphate basis from a merely
“bridging” to a “bone-reconstructive” function turns
those materials into an applicable alternative for the
respective indications.
Particularly in elderly prosthodontic patients, the
clinician faces a reduced bone supply as a result of
Figure 4. A. Intrabony defect before treatment; B. Periodontal
regeneration of intrabony defect after treatment with Enamel
Matrix Derivatives.
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progressive atrophy of the alveolar ridge. As an ex-
ample, Tiolox implants (Tiolox, Implants GmbH, Den-
taurum Company) are demonstrated in regions 43,
44, 46, and 47 with vestibular bone deficit after im-
plantation. The defects have been covered using bone
grafts, which were harvested during preparation of
the implant bed.
Additionally, Biogran (Fa. 3i) was applied in the
two distal implants. The relatively large augmenta-
tion areas were covered by a titan mesh, Tiomesh
(Tiolox Implants GmbH, Dentaurum Company, Isprin-
gen) for material fixation. The titan mesh was fixed
to the implant by means of the cover screw (Fig. 5).
In the regenerative therapy of multi-factorial fun-
nel-shaped and slit-shaped peri-implant defects with
progressive bone resorption both the membrane
technique associated with frequent premature mem-
brane exposure [4] and the use of bone substitutes [10]
are a subject of controversy. In contrast, defect fill-
ing using autogenous bone grafts without mem-
brane coverage yields far better results [1].
PROSPECTS
As well as the integration of enamel matrix de-
rivatives into surgical periodontal therapy as a novel
regenerative technique the application of “tissue
engineering” from patient cells also permits the
production of very well tolerated tissue transplants.
3D cultivation of human mesenchymal stem cells and
osteogenous differentiation for bone tissue produc-
tion are already performed in many laboratories.
However, a large-scale clinical application of “tissue
engineering” in the treatment of periodontal bone
defects is not yet possible.
In the near future industrially manufactured bio-
materials are likely to be applied in combination with
laboratory-grown cells.
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